Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jul 27, 2026
Vyne Therapeutics Inc. (VYNE)
A forensic read on Vyne Therapeutics Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Distress
Financial health
-70.3
Altman Z-score
Watch
Earnings quality
3
Forensic signals
-95.4%
ROE
13.8%
Revenue growth
Financial health / Altman Z-score above is based on book value, not market value — this free snapshot doesn't pull live market data. Treat it as a rough read, not the final word.
Vyne Therapeutics Inc. earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is -70.3, placing it in the Distress zone (based on book value, not market value, since this free snapshot doesn't pull live market data — treat this zone as a rough read, not the final word). 3 forensic signals were flagged in its latest SEC filings, led by share count (stock split).
What the filings flag
n/m (stock split)
FY2022–FY2025
Share count (stock split).Diluted share count changed +1242% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +137.7%/yr figure isn't a real buyback/dilution read here.
405% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 405% of revenue in FY2025 — about $0.05 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
$4M
FY2020–FY2020
Goodwill impairments.Took $4M of goodwill writedowns across 1 year (FY2020 ($4M)). Writedowns mean past acquisitions underperformed what was paid for them — worth weighing on capital-allocation skill.
Key fundamentals
Latest Revenue$570,000.00
Revenue Growth YoY+13.8%
Revenue CAGR (3yr)+6.1%
Net Margin-4646.1%
Free Cash Flow$-25.7M
Return on Equity-95.4%
Debt / Equity0.00x
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Vyne Therapeutics Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about VYNE's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown